AccessDx Laboratory, a global provider of advanced laboratory diagnostics solutions and a portfolio company of Access DX Holdings, is proud to announce that Vice President of Clinical Operations Houda Hachad, PharmD, M. Res., has been named to the 2022 PharmaVoice 100 – a recognition of the most inspiring people in the life-sciences industry.
Dr. Hachad was selected based on the many advancements she has made in the areas of genetics and genomics and her strong commitment to improving drug safety. At AccessDx, Dr. Hachad develops new technologies and oversees initiatives that help get ahead of some of the 46 million adverse drug reactions each year caused by genetic factors that impact patients’ drug metabolization. Her work focuses on managing drug-gene interaction data and making it accessible to clinicians, ultimately empowering them to curb excess hospitalizations and extraneous costs while improving patient outcomes.
Earlier in her career, Dr. Hachad co-invented several databases – Drug Interaction Database, e-PKgene and Clinical Pharmacogenomics Solutions – supporting drug development companies, regulatory agencies, scientists, diagnostic organizations, and healthcare institutions around the globe in their research and drug safety efforts.
“Dr. Hachad’s research, expertise, and contributions have been used by a generation of clinical, pharmacy, and laboratory professionals to positively impact patient care,” said Bryon Cipriani, CEO of AccessDx Laboratory. “Dr. Hachad’s commitment to research initiatives, as well as mentioning the next generation of precision medicine professionals, serves as an inspiration to her colleagues here at AccessDx and the community at large. We’re very proud to celebrate her recognition as part of the PharmaVoice 100.”
PharmaVoice’s annual awards program recognizes individuals representing all sectors of the life-sciences industry – from academia to nonprofit organizations to big pharma to emerging biotech companies to technology companies to commercial organizations that provide molecule-to-market services in support of moving the needle to benefit patients around the world. Honorees are selected from a pool of nominations submitted by readers and evaluated by the PharmaVoice team. The 2022 winners will be formally recognized on September 15, 2022, at a virtual celebration (more details available here).
“It is always an honor to showcase these inspiring individuals whose leadership over the past 18 months has been more important than ever to make sure their teams, the patients they serve, and their organizations continue to excel at the highest levels possible,” said Taren Grom, PharmaVoice Editor in Chief Emeritus.
About AccessDx Laboratory
AccessDx Laboratory is a CLIA-certified, CAP-accredited, and NYCQ diagnostic laboratory dedicated to providing clinical insights that improve patient outcomes. AccessDx diagnostic solutions include COVID-19 testing, pharmacogenomic (PGx) testing, cancer genomic (CGx) testing, respiratory pathogen panels, and a wide range of other clinical laboratory services. AccessDx diagnostic and software solutions are currently trusted by thousands of clinical providers in health systems nationwide. For more information, please visit www.AccessDxLab.com.
PharmaVoice is a leading industry publication operated by Industry Dive. Its stories deliver the most important voices and ideas in the life sciences to industry leaders.
About Industry Dive
Industry Dive is a leading business journalism company. Nearly 13 million decision-makers across 24 competitive industries rely on its exclusive insight and analysis delivered through 27 publications.